Genoa Pharmaceuticals Finds $1.2M

San Diego-based biotechnology company Genoa Pharma announced this morning that it has raised $1.2M in a finacing round, to help advance its treatments for Idiopathic Pulmonary Fibrosis (IPF). Source of the seed funding was not announced. IPF is a fatal lung disease which the company says affects approximately 200,000 Americans and 135,000 Europeans. Genoa Pharmaceuticals was founded by Mark SUrber, Ph.D., who has formerly served at Mpex and Aires Pharmaceuticals. The company said that the only treatment available to patients today is a lung transplant, as there are no U.S. approved drugs for IPF. More information »